Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-26
2011-07-26
Harris, Alana M (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S380000, C530S386000, C530S387100, C530S387300, C530S387700, C530S388100, C530S391100, C530S391300, C530S391500, C530S391700, C530S391900
Reexamination Certificate
active
07985843
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.
REFERENCES:
patent: 5279966 (1994-01-01), Jessell et al.
patent: 5585232 (1996-12-01), Farr
patent: 5589337 (1996-12-01), Farr
patent: 5849480 (1998-12-01), Cros et al.
patent: 6525023 (2003-02-01), Yamasaki et al.
patent: 6617109 (2003-09-01), Xu et al.
patent: 6710170 (2004-03-01), Xu et al.
patent: 7598051 (2009-10-01), Fanger et al.
patent: 2002/0132237 (2002-09-01), Algate et al.
patent: 2370489 (2000-10-01), None
patent: 20103510 (1998-08-01), None
patent: 1067182 (2001-01-01), None
patent: 6-303997 (1994-11-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 94/12881 (1994-06-01), None
patent: WO 95/14772 (1995-06-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 99/04265 (1999-01-01), None
patent: WO 00/52044 (2000-09-01), None
patent: WO 00/61629 (2000-10-01), None
patent: WO 00/77026 (2000-12-01), None
patent: WO 01/36685 (2001-05-01), None
patent: WO 01/47944 (2001-07-01), None
patent: WO 01/81634 (2001-11-01), None
patent: WO 01/92581 (2001-12-01), None
patent: WO 01/93983 (2001-12-01), None
patent: WO 02/08288 (2002-01-01), None
Genbank Database, Accession No. AF034633, Dec. 1, 1997.
Chen, L. et al., “Increased expression of cerulopladmin in the retina following photic injury,”Molecular Vision 9: 151-158, 2003.
Curti, B.D., “Physical barriers to drug delivery in tumors,”Critical Reviews in Oncology/Hematology 14: 29-39, 1993.
Database EMBL Acccession No. AA536804, Jul. 31, 1997.
Database EMBL Accession No. AC016957, Dec. 14, 1999.
Database EMBL, Accession No. AF060226, May 6, 1998.
Database EMBL, Accession No. AX001326, Mar. 10, 2000.
Database EMBL, Accession No. X02662, May 7, 1999.
EMBL-EBI Database, Accession No. BE378674, Jul. 29, 2000.
EMBL-EBI Database, Accession No. BE385990, Jul. 29, 2000.
EMBL-EBI Database, Accession No. BE395581, Jul. 29, 2000.
EMBL-EBI Database, Accession No. BE395797, Jul. 29, 2000.
EMBL-EBI Database, Accession No. BE746601, Sep. 20, 2000.
EMBL-EBI Database, Accession No. BF125134, Oct. 26, 2000.
EMBL-EBI Database, Accession No. BF345141, Nov. 27, 2000.
GenBank Database, Accession No. AA173383, Sep. 30, 1997.
GenBank Database, Accession No. AA173739, Sep. 30, 1997.
GenBank Database, Accession No. AA223587, Feb. 19, 1997.
GenBank Database, Accession No. AA281245, Jan. 14, 1998.
GenBank Database, Accession No. AAH17318, Oct. 4, 2003.
GenBank Database, Accession No. AB041649, Jun. 30, 2000.
GenBank Database, Accession No. AF161511, Jun. 23, 1999.
GenBank Database, Accession No. AI023799, Aug. 28, 1998.
GenBank Database, Accession No. AI307373, Apr. 8, 1999.
GenBank Database, Accession No. AI360254, Feb. 16, 1999.
GenBank Database, Accession No. AI936826, Mar. 8, 2000.
GenBank Database, Accession No. AK012406, Sep. 2, 2005.
GenBank Database, Accession No. AW149665, Nov. 3, 1999.
GenBank Database, Accession No. AW150789, Nov. 3, 1999.
GenBank Database, Accession No. AW377176, Apr. 7, 1998.
GenBank Database, Accession No. AW406327, Oct. 30, 1998.
GenBank Database, Accession No. AX136281, May 30, 2001.
GenBank Database, Accession No. BAA95101, Jun. 30, 2000.
GenBank Database, Accession No. BC011449, Aug. 19, 2003.
GenBank Database, Accession No. BC017318, Oct. 4, 2003.
Genbank Database, Accession No. H06756, Jun. 21, 1995.
GenBank Database, Accession No. L19184, Oct. 13, 1994.
GenBank Database, Accession No. NM—001508, Dec. 15, 1997.
GenBank Database, Accession No. NP—001499, Dec. 15, 1997.
GenCore Database, Accession No. Q9JJ96, Oct. 1, 2000.
GenBank Database, Accession No. R60095, Apr. 14, 1993.
GenBank Database, Accession No. Z95125, Sep. 27, 1997.
Genseq (Derwent) Database, Accession No. AAK54063, Nov. 16, 2001.
Genseq (Derwent) Database, Accession No. AAL27277, Jan. 24, 2002.
Genseq (Derwent) Database, Accession No. AAL33984, Jan. 24, 2002.
Genseq (Derwent) Database, Accession No. AAL33985, Jan. 24, 2002.
Genseq (Derwent) Database, Accession No. AAL33986, Jan. 24, 2002.
Genseq (Derwent) Database, Accession No. AAU83599, May 8, 2002.
Gerhold, D. et al., “It's the genes! EST access to human genome content,” BioEssays 18(12): 973-981, 1996.
Gibson et al., “Novel method for real time quantitative RT-PCR,” Genome Research 6:995-1001, Oct. 1996.
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,” Science 278:1041-1042, Nov. 7, 1997.
Hartwell, L.H. et al., “Integrating Genetic Approaches into the Discovery of Anticancer Drugs,” Science 278: 1064-1068, Nov. 7, 1997.
Haynes, P.A. et al., “Proteome analysis: Biological assay or data archive?,” Electrophoresis 19: 1862-1871, 1998.
Heid et al., “Real time quantitative PCR,” Genome Research 6:986-994, Oct. 1996.
Houghton, A.N. et al., “Monoclonal Antibodies: Potential Applications to the Treatment of Cancer,” Seminars in Oncology 13(2): 166-179, Jun. 1986.
Hu, Y. et al., “Analysis of Genomic and Proteomic Data Using Advanced Literature Mining,” Journal of Proteome Research 2: 405-412, 2003.
Jain, R.K., “Barriers to Drug Delivery in Solid Tumors,” Scientific American 271: 58-65, Jul. 1994.
McKee, K.K. et al., “Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensis receptors,” Genomics 46(3): 426-434, 1997.
Meden and Kuhn, “Overexpression of the oncogene c-crbB-2 (HER2
eu) in ovarian cancer: a new prognostic factor,” European Journal of Obstetrics & Gynecology and Reproductive Biology 71:173-179, 1997.
Nagase et al, “Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro,” DNA Research 5(5): 277-286, 1998.
Novocastra Laboratories Ltd., Data Sheet, Mesothelin, NCL-L-MESO, Feb. 2004.
Prydz, K. et al., “Cholesterol depletion deduces apical transport capacity in epithelial Madin-Darby canine kidney cells,” Biochemical Journal 357: 11-15, 2001.
Russell, R.B. et al., “Structural Features can be Unconserved in Proteins with Similar Folds,” J. Mol. Biol. 244: 332-350, 1994.
Schena et al., “Quantitative monitoring of gene expression patterns with a complementary DNA microarray,” Science 270:467-470, Oct. 20, 1995.
Tascilar, M. et al., “Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer,”Annals of Oncology 10(Suppl. 4):S107-S110, 1999.
Tockman, M.S. et al., “Considerations in Bringing a Cancer Biomarker to Clinical Application,”Cancer Research 52(Suppl):2711s-2718s, May 1, 1992.
Wells, T.N.C. et al., “The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and Expressed Sequence Tag Databases,” Journal of Leukocyte Biology 61(5): 545-550, May 1997.
Winter, G. et al., “Humanized antibodies,” Trends in Protein Sciences 14: 139-143, May 1993.
Fanger Gary R.
Fling Steven P.
Corixa Corporation
Harris Alana M
Seed IP Law Group PLLC
LandOfFree
Compositions and methods for the therapy and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the therapy and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the therapy and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2739329